A 35-year-old man with moderate persistent asthma is on regular budesonide (ICS) and formoterol (LABA) combination inhaler. He is counselled on correct inhaler technique and trigger avoidance. Which of the following statements about his current management is NOT correct?

Explanation

## ICS + LABA Combination Therapy: Role and Limitations **Key Point:** While ICS + LABA combinations are highly effective maintenance therapy, they do NOT eliminate the need for a separate SABA rescue inhaler. Even well-controlled asthma can have breakthrough symptoms or acute exacerbations. ### Correct Principles of ICS + LABA Use | Principle | Evidence | |-----------|----------| | Maintenance therapy | Reduces exacerbations by 50–70% vs. ICS alone | | MART regimen | Some ICS + LABA inhalers (e.g., budesonide/formoterol) can be used as both maintenance AND reliever | | SABA availability | **Always** keep a separate SABA for breakthrough symptoms | | Adherence benefit | Reduces hospitalizations and oral steroid courses | | Acute exacerbation | SABA + systemic corticosteroid, not ICS + LABA alone | **High-Yield:** The MART (Maintenance and Reliever Therapy) approach with ICS + LABA inhalers is endorsed by GINA and reduces exacerbations further than traditional ICS + LABA + separate SABA. However, a rescue SABA must still be available. ### Why Option 3 Is Wrong Even with perfect adherence to ICS + LABA maintenance therapy: - Breakthrough symptoms occur in ~10–20% of patients - Acute exacerbations can happen despite good control - SABA provides rapid relief that ICS + LABA cannot match (LABA onset is 15–30 min) - Guideline-concordant care mandates SABA availability **Clinical Pearl:** A patient who claims they "never need" a rescue inhaler may have poor symptom recognition or be at risk of near-fatal asthma. Always ensure SABA access. ### Asthma Control and Treatment Escalation ```mermaid flowchart TD A[Asthma diagnosis]:::outcome --> B{Frequency of symptoms?}:::decision B -->|Intermittent| C[SABA PRN only]:::action B -->|Mild persistent| D[ICS low-dose]:::action D --> E{Controlled?}:::decision E -->|Yes| F[Continue ICS]:::action E -->|No| G[Add LABA or increase ICS]:::action G --> H[ICS + LABA]:::action H --> I{Controlled?}:::decision I -->|Yes| J[Maintain ICS + LABA + SABA PRN]:::action I -->|No| K[Add LTRA or increase ICS dose]:::action L[Any asthma patient]:::outcome --> M[SABA always available]:::urgent ``` **Mnemonic:** **"ICS + LABA + SABA"** — the triple-threat rule. Even on combination therapy, SABA is non-negotiable.